You just read:

Regeneron and Sanofi Receive Positive CHMP Opinion for Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis

News provided by

Regeneron Pharmaceuticals, Inc.

Jul 21, 2017, 07:30 ET